Biological determinants of responsiveness to growth hormone: pharmacogenomics and personalized medicine.
نویسنده
چکیده
It is becoming most clear that many genes are involved in controlling the regulation of growth. Ultimately however, at the level of growth hormone (GH), the relevant question may be not whether a patient is GH-deficient, but whether he is GH-responsive. As these disturbances can be divided into two gross categories, namely alterations causing subnormal GH secretion and/or those presenting with subnormal GH sensitivity/responsiveness, the main aim of this review is to focus on genes involved in growth regulation leading to short stature caused by an alteration of GH insensitivity/GH responsiveness; in other words, clinical circumstances where individually adapted GH replacement therapy may help to increase height velocity and eventually final height.
منابع مشابه
Use of pharmacogenomics in psoriasis
ISSN 2041-6792 10.4155/CLI.11.11 © 2011 Future Science Ltd Patients with moderate-to-severe psoriasis frequently require treatment with systemic or biologic therapies, but considerable interpatient variability is observed in both clinical responsiveness and toxicity relating to these agents. Thus, identifying patients with a greater risk of treatment toxicity or nonresponse prior to treatment i...
متن کاملPharmacogenomics approach in psychiatry disorders
Psychiatric disorders are important health issues in the world, and their management is facing some serious challenges. Drugs that are widely used in the treatment of psychiatric disorders, including antidepressants, antipsychotics, and mood stabilizers, are often associated with many side effects and are adequately effective only in a small proportion of patients. Many factors, including genet...
متن کاملA Conceptual model on the pharmacogenomics implementation complications: An applied qualitative research based on national drug policy components
Introduction: Pharmacogenomics may well have substantial effects on the clinical, economic and regulatory aspects of health sector; which can lead to complications in access. Therefore, there is a need for evidence-based frameworks based on national drug policy components. The objective of the current study is to identify pharmacogenomics-based complications and develop a conceptual model. Mate...
متن کاملPharmacogenomics of glibenclamide in patients with type 2 diabetes mellitus: A systematic review
Introduction: One of the most widely used anti-diabetic drugs is sulfonylureas, which is often used as one of the first-line drugs in the treatment of type 2 diabetes. Due to the effect of the patient's genetic structure on the drug response (personalized medicine), the identification of genetic variations not only reduces the rate of adverse drug reactions but can also predict the effectivenes...
متن کاملMicroRNA binding site polymorphisms as biomarkers in cancer management and research
MicroRNAs (miRNAs) are important regulators of eukaryotic gene expression. They have been implicated in a broad range of biological processes, and miRNA-related genetic alterations probably underlie several human diseases. Single nucleotide polymorphisms of transcripts may modulate the posttranscriptional regulation of gene expression by miRNAs and explain interindividual variability in cancer ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Endocrine development
دوره 18 شماره
صفحات -
تاریخ انتشار 2010